Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than a buck. -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (384)	2/10/2000 12:55:00 AM
From: BulbaMan	Respond to of 743

Took a quick look at CIST and it seems to be worth quite a bit more than the $.40 it's trading at. Book value is about $.50 a share and this comes from real money: cash and payments due to them from Immunex in 2000 and 2001 as a result of their patent litigation settlement. Along with their cash, there's additional value in their intellectual property (they have a vaccine adjuvant deal with Pasteur Merieux that could pay off nicely down the road) and accumulated tax losses. It appears the company will be sold in the near future and, given the above, my guess is it'll go for more than $.40. Has anyone else checked CIST out?